Equities Analysts Offer Predictions for CRVS FY2024 Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Stock analysts at Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for shares of Corvus Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($0.91) for the year, down from their prior estimate of ($0.50). The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.68) per share.

Other equities analysts also recently issued research reports about the company. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. LADENBURG THALM/SH SH lifted their target price on Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Oppenheimer increased their price target on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, StockNews.com cut Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.83.

Corvus Pharmaceuticals Stock Performance

CRVS stock opened at $8.34 on Monday. The stock’s 50 day simple moving average is $6.83 and its 200 day simple moving average is $4.08. The company has a market cap of $535.90 million, a P/E ratio of -9.32 and a beta of 1.05. Corvus Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $10.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CRVS. Cubist Systematic Strategies LLC bought a new stake in Corvus Pharmaceuticals in the second quarter worth $44,000. Nwam LLC purchased a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $53,000. XTX Topco Ltd bought a new stake in shares of Corvus Pharmaceuticals in the 3rd quarter valued at about $74,000. Oppenheimer & Co. Inc. purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at about $89,000. Finally, Marshall Wace LLP bought a new position in Corvus Pharmaceuticals during the 2nd quarter worth approximately $136,000. 46.64% of the stock is currently owned by institutional investors.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.